These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 18344762)

  • 21. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
    Del Amo EM; Urtti A
    Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progression of drug delivery system for glaucoma].
    Xu Y; Lyu L
    Zhonghua Yan Ke Za Zhi; 2014 Dec; 50(12):946-51. PubMed ID: 25619186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT.
    Andrés-Guerrero V; Alarma-Estrany P; Molina-Martínez IT; Peral A; Herrero-Vanrell R; Pintor J
    Exp Eye Res; 2009 Mar; 88(3):504-11. PubMed ID: 19056382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposomes in topical ophthalmic drug delivery: an update.
    Agarwal R; Iezhitsa I; Agarwal P; Abdul Nasir NA; Razali N; Alyautdin R; Ismail NM
    Drug Deliv; 2016 May; 23(4):1075-91. PubMed ID: 25116511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Compliance in glaucoma].
    Stefan C; Dumitrică DM
    Oftalmologia; 2008; 52(3):7-9. PubMed ID: 19149111
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of eyedrops in glaucoma: how can we help to reduce non-compliance?
    Chawla A; McGalliard JN; Batterbury M
    Acta Ophthalmol Scand; 2007 Jun; 85(4):464. PubMed ID: 17286557
    [No Abstract]   [Full Text] [Related]  

  • 27. Current and new pharmacotherapeutic approaches for glaucoma.
    Shalaby WS; Shankar V; Razeghinejad R; Katz LJ
    Expert Opin Pharmacother; 2020 Nov; 21(16):2027-2040. PubMed ID: 32717157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical therapies for glaucoma and ocular hypertension: an update on current practice.
    Rouland JF
    Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S1-4. PubMed ID: 14628758
    [No Abstract]   [Full Text] [Related]  

  • 29. Programs to optimize adherence in glaucoma.
    Kowing D; Messer D; Slagle S; Wasik A;
    Optometry; 2010 Jul; 81(7):339-50. PubMed ID: 20630372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topical estrogen drops may be a new alternative in the treatment of glaucoma.
    Ozcura F; Aydin S
    Med Hypotheses; 2007; 69(2):456. PubMed ID: 17222989
    [No Abstract]   [Full Text] [Related]  

  • 31. Nanotechnology in ocular drug delivery.
    Sahoo SK; Dilnawaz F; Krishnakumar S
    Drug Discov Today; 2008 Feb; 13(3-4):144-51. PubMed ID: 18275912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained drug delivery in glaucoma.
    Knight OJ; Lawrence SD
    Curr Opin Ophthalmol; 2014 Mar; 25(2):112-7. PubMed ID: 24463419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.
    Furrer E; Berdugo M; Stella C; Behar-Cohen F; Gurny R; Feige U; Lichtlen P; Urech DM
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):771-8. PubMed ID: 18757508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should patients choose their own eyedrops?
    Buller A; Hercules BL
    Acta Ophthalmol Scand; 2006 Feb; 84(1):150-1. PubMed ID: 16445459
    [No Abstract]   [Full Text] [Related]  

  • 35. Nerve growth factor eye drops to treat glaucoma.
    Lambiase A; Mantelli F; Bonini S
    Drug News Perspect; 2010; 23(6):361-7. PubMed ID: 20697603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical treatment of glaucoma: present and future.
    Fogagnolo P; Rossetti L
    Expert Opin Investig Drugs; 2011 Jul; 20(7):947-59. PubMed ID: 21534887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noninvasive ocular drug delivery: potential transcorneal and other alternative delivery routes for therapeutic molecules in glaucoma.
    Foldvari M
    J Glaucoma; 2014; 23(8 Suppl 1):S80-2. PubMed ID: 25275915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timolol transport from microemulsions trapped in HEMA gels.
    Li CC; Abrahamson M; Kapoor Y; Chauhan A
    J Colloid Interface Sci; 2007 Nov; 315(1):297-306. PubMed ID: 17673246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients.
    Olthoff CM; Hoevenaars JG; van den Borne BW; Webers CA; Schouten JS
    Graefes Arch Clin Exp Ophthalmol; 2009 Feb; 247(2):235-43. PubMed ID: 18802720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.